Академический Документы
Профессиональный Документы
Культура Документы
OUTLINE
Dysfunctional uterine bleeding (DUB)
Aim of investigation
Investigations
History
Internal examination
Special investigation
Management
Medical
Non-hormonal
Surgical
2
DYSFUNCTIONAL UTERINE
BLEEDING
Defined as:
A state of abnormal uterine bleeding
WITHOUT any clinically detectable
organic, systemic and iatrogenic cause.
INCIDENCE
DUB occur in:
50% before menopause
30% reproductive age
20% adolescence
Thus, the abnormal bleeding may be
associated with or without ovulation and
accordingly grouped into:
l
Anovular
bleeding
Ovular bleeding
4
ANOVULAR BLEEDING
Have
developing
follicle
Alteration of
Absence of
prostaglandin
progesterone
No mature
production
Endometrial follicle
growth
under influence
Increase PGE2 and
No the
corpus
estrogen through
PGI2
cycle
luteum
Only have
Inadequatestructural
Vasodilate,
stromal support
increase
estrogen, but fibrinolytic
activity
no progestrone
No ovulation occur
Remain fragile
BLEEDING
OVULAR BLEEDING
Irregular ripening of
endometrium
Irregular shedding of
endometrium
6
OVULAR BLEEDING
IRREGULAR RIPENNG OF
ENDOMETRIUM
Inadequate formation
and function of corpus
luteum
Luteal phase is short
Inadequate secretion
of progesterone and
estrogen
IRREGULAR SHEDDING OF
ENDOMETRIUM
Incomplete withdrawal of LH
incomplete atrophy of
Corpus Luteum persistent
secretion of Progesterone
Persistant LHinhibit
FSHsuppresses ripening of
follicle in next cycle less
Estrogen less regeneration
Clinical presentation:
Clinical presentation :
polymenorrhea
AIMS OF INVESTIGATION
To confirm the menstrual abnormality
as stated by patient
To exclude the systemic, iatrogenic
and organic pelvic pathology
To identify possible etiology of DUB
To workout definite therapy protocol
HISTORY
1. Firstly to confirm the
bleeding is through
vagina, not the urethra
or rectum.
2. Excessive bleeding
assessment?
* If ambiguity is found, it is
better to assess by admitting
the patient during period.
3. Nature of menstrual
abnormality
Cyclic or acyclic
Last normal cycle
INTERNAL EXAMINATION
To exclude palpable pelvic pathology.
Bimanual examination including speculum
examination should be done in all cases
except in virgins.
Rectal examination
10
SPECIAL
INVESTIGATION
Full blood
count
(FBC)
Colour
Doppler
Transvagin
al
sonograph
y (TVS)
Hysterosco
py
Saline
infusion
sonograph
y (SIS)
D&C
Endometri
al
sampling
Laparosco
py
SPECIAL INVESTIGATIONS
1. Full blood count
Hb level
Platelet count
Prothrombin time
Bleeding time
PTT
TSH, T3 and T4 for suspected thyroid cases
12
3. Color Doppler
13
5. Hysteroscopy
6. Endometrial sampling
As outpatient basis
Pipelle sampler a blind procedure
hence IU pathology (polyps, submucous
fibroids) cannot be detected.
7. Laparoscopy
14
15
16
Medical
Management
Orally
active
progestins
IU
progestog
en
Estrogen
Danazol
GnRH
agonist
Mifepriston
e
5TH-25TH day
ORALLY
ACTIVE
PROGESTIN
CYCLIC
15th-25th day
CONTINUOU
S
MEDICAL MANAGEMENT
ORALLY ACTIVE PROGESTINS
Common preparations used are
norethisterone acetate and
medroxyprogesterone acetate.
Isolated PG is highly effective in
anovular DUB.
Combined PG&E are effective in
ovular DUB.
19
Preparation used
Cyclic therapy
Continuous therapy
Norethisterone preparations
5mg tablet
3x daily until bleeding stops, usually
3-7 days
20
CYCLIC THERAPY
5th 25th day
course
5th 25th day course
In ovular bleeding, any low dose OCP
are effective, given from 5th to 25th
day of cycle for 3 consecutive cycles.
More effective than PG as it suppress
HP axis more effectively.
Normal menstruation is expected.
Reduce menstrual blood loss by 50%.
Serves as contraceptive as well.
In anovular bleeding, cyclic PG of
medroxyprogesterone acetate (MPA)
10mg, or
Norethisterone 5mg
From 5th to 25th day of cycle for 3
cycles
CONTINUOUS PROGESTINS
Medroxyprogesterone acetate (MPA)
10mg thrice daily, continued for at
least 90 days.
Preparations are various:
Oral
Long-acting IM injections
DMPA implants
Progesterone only pill
* Effective in reducing menstrual blood loss
but may also result in oligomenorrhea or
amenorrhea
22
23
ESTROGEN:
in situations where bleeding is acute and severe,
conjugated estrogen 25mg IV is given.
Mechanisms:
Helps with rapid growth of denuded endometrium
and promotes platelet adhesiveness.
Controls bleeding by process of healing.
Proliferation of endometrium, increase level of
fibrinogen, factors V, X and platelet aggregation.
24
IU progestogen
Levonorgestrel intrauterine system (LNGIUS) induce endometrial glandular atrophy,
stromal decidualization and endometrial cell
inactivation.
Effective for 5 years.
Reduction of blood loss is upto 97%.
25
Mifepristone
An antiprogesterone.
Inhibits ovulation and induce amenorrhea.
GnRH agonists
Subtherapeutic doses reduce blood loss,
therapeutic doses produce amenorrhea.
Valuable as short-term use in severe DUB
(infertile & wants pregnancy).
SC or intranasal
Improves anemia & helpful when used before
ablation.
26
NON-HORMONAL
MANAGEMENT
Anti-fibrinolytic agents (Tranexamic acid)
It counteracts endometrial fibrinolytic system.
GI side effects are common.
Can be used as second line therapy.
27
Desmopressin
A synthetic analogue of argininevasopressin
Especially indicated in cases with von
Willebrands disease and factor VIII
deficiency.
Given IV 0.3g/kg or intranasally.
28
SURGICAL MANAGEMENT
Uterine curettage
Hemostatic and therapeutic effect by removing
necrosed and unhealthy endometrium.
Done following USG.
Indication: Urgent, acyclic bleeding & endometrial
pathology is suspected.
Endometrial ablation
Indications:
Hysterectomy
Not recommended as first line therapy for heavy
menstrual bleeding (HMB) or DUB.
Indication: when conservative treatment fails or
contraindicated, and blood loss impairs health and
life quality, presence of endometrial hyperplasia
and atypia.
Routes of procedures: vaginal, abdominal or
laparoscopic assisted vaginal method (less invasive)
Depending on uterine size, mobility, descent,
previous surgery and cormobidities (obesity,
diabetes, heart disease or hypertension).
30
REFERENCE
Duttas Textbook of Gynaecology, 6th
Edition
Gynaecology by Ten Teachers
http://www.acog.org/Patients/FAQs/En
dometrial-Hyperplasia
31